Comparison of treatment results between 3- And 2-stage Gamma Knife radiosurgery for large brain metastases

A retrospective multi-institutional study

Toru Serizawa, Yoshinori Higuchi, Masaaki Yamamoto, Shigeo Matsunaga, Osamu Nagano, Yasunori Sato, Kyoko Aoyagi, Shoji Yomo, Takao Koiso, Toshinori Hasegawa, Kiyoshi Nakazaki, Akihito Moriki, Takeshi Kondoh, Yasushi Nagatomo, Hisayo Okamoto, Yukihiko Kohda, Hideya Kawai, Satoka Shidoh, Toru Shibazaki, Shinji Onoue & 3 others Hiroyuki Kenai, Akira Inoue, Hisae Mori

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: In order to obtain better local tumor control for large (i.e., > 3 cm in diameter or > 10 cm3 in volume) brain metastases (BMs), 3-stage and 2-stage Gamma Knife surgery (GKS) procedures, rather than a palliative dose of stereotactic radiosurgery, have been proposed. Here, authors conducted a retrospective multi-institutional study to compare treatment results between 3-stage and 2-stage GKS for large BMs. Methods: This retrospective multi-institutional study involved 335 patients from 19 Gamma Knife facilities in Japan. Major inclusion criteria were 1) newly diagnosed BMs, 2) largest tumor volume of 10.0-33.5 cm3, 3) cumulative intracranial tumor volume ≤ 50 cm3, 4) no leptomeningeal dissemination, 5) no more than 10 tumors, and 6) Karnofsky Performance Status 70% or better. Prescription doses were restricted to between 9.0 and 11.0 Gy in 3-stage GKS and between 11.8 and 14.2 Gy in 2-stage GKS. The total treatment interval had to be within 6 weeks, with at least 12 days between procedures. There were 114 cases in the 3-stage group and 221 in the 2-stage group. Because of the disproportion in patient numbers and the pre-GKS clinical factors between these two GKS groups, a case-matched study was performed using the propensity score matching method. Ultimately, 212 patients (106 from each group) were selected for the case-matched study. Overall survival, tumor progression, neurological death, and radiation-related adverse events were analyzed. Results: In the case-matched cohort, post-GKS median survival time tended to be longer in the 3-stage group (15.9 months) than in the 2-stage group (11.7 months), but the difference was not statistically significant (p = 0.65). The cumu-lative incidences of tumor progression (21.6% vs 16.7% at 1 year, p = 0.31), neurological death (5.1% vs 6.0% at 1 year, p = 0.58), or serious radiation-related adverse events (3.0% vs 4.0% at 1 year, p = 0.49) did not differ significantly. Conclusions: This retrospective multi-institutional study showed no differences between 3-stage and 2-stage GKS in terms of overall survival, tumor progression, neurological death, and radiation-related adverse events. Both 3-stage and 2-stage GKS performed according to the aforementioned protocols are good treatment options in selected patients with large BMs.

Original languageEnglish
Pages (from-to)227-237
Number of pages11
JournalJournal of neurosurgery
Volume131
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1
Externally publishedYes

Fingerprint

Radiosurgery
Neoplasm Metastasis
Brain
Therapeutics
Radiation
Neoplasms
Tumor Burden
Survival
Karnofsky Performance Status
Propensity Score
Clinical Protocols
Prescriptions
Japan
Incidence

Keywords

  • Case-matched study
  • Competing risk analysis
  • Large brain metastases
  • Multi-institutional cooperative study
  • Oncology
  • Staged Gamma Knife surgery
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Comparison of treatment results between 3- And 2-stage Gamma Knife radiosurgery for large brain metastases : A retrospective multi-institutional study. / Serizawa, Toru; Higuchi, Yoshinori; Yamamoto, Masaaki; Matsunaga, Shigeo; Nagano, Osamu; Sato, Yasunori; Aoyagi, Kyoko; Yomo, Shoji; Koiso, Takao; Hasegawa, Toshinori; Nakazaki, Kiyoshi; Moriki, Akihito; Kondoh, Takeshi; Nagatomo, Yasushi; Okamoto, Hisayo; Kohda, Yukihiko; Kawai, Hideya; Shidoh, Satoka; Shibazaki, Toru; Onoue, Shinji; Kenai, Hiroyuki; Inoue, Akira; Mori, Hisae.

In: Journal of neurosurgery, Vol. 131, No. 1, 01.01.2019, p. 227-237.

Research output: Contribution to journalArticle

Serizawa, T, Higuchi, Y, Yamamoto, M, Matsunaga, S, Nagano, O, Sato, Y, Aoyagi, K, Yomo, S, Koiso, T, Hasegawa, T, Nakazaki, K, Moriki, A, Kondoh, T, Nagatomo, Y, Okamoto, H, Kohda, Y, Kawai, H, Shidoh, S, Shibazaki, T, Onoue, S, Kenai, H, Inoue, A & Mori, H 2019, 'Comparison of treatment results between 3- And 2-stage Gamma Knife radiosurgery for large brain metastases: A retrospective multi-institutional study', Journal of neurosurgery, vol. 131, no. 1, pp. 227-237. https://doi.org/10.3171/2018.4.JNS172596
Serizawa, Toru ; Higuchi, Yoshinori ; Yamamoto, Masaaki ; Matsunaga, Shigeo ; Nagano, Osamu ; Sato, Yasunori ; Aoyagi, Kyoko ; Yomo, Shoji ; Koiso, Takao ; Hasegawa, Toshinori ; Nakazaki, Kiyoshi ; Moriki, Akihito ; Kondoh, Takeshi ; Nagatomo, Yasushi ; Okamoto, Hisayo ; Kohda, Yukihiko ; Kawai, Hideya ; Shidoh, Satoka ; Shibazaki, Toru ; Onoue, Shinji ; Kenai, Hiroyuki ; Inoue, Akira ; Mori, Hisae. / Comparison of treatment results between 3- And 2-stage Gamma Knife radiosurgery for large brain metastases : A retrospective multi-institutional study. In: Journal of neurosurgery. 2019 ; Vol. 131, No. 1. pp. 227-237.
@article{022cdf28e9854649a224d9488e86ff80,
title = "Comparison of treatment results between 3- And 2-stage Gamma Knife radiosurgery for large brain metastases: A retrospective multi-institutional study",
abstract = "Objective: In order to obtain better local tumor control for large (i.e., > 3 cm in diameter or > 10 cm3 in volume) brain metastases (BMs), 3-stage and 2-stage Gamma Knife surgery (GKS) procedures, rather than a palliative dose of stereotactic radiosurgery, have been proposed. Here, authors conducted a retrospective multi-institutional study to compare treatment results between 3-stage and 2-stage GKS for large BMs. Methods: This retrospective multi-institutional study involved 335 patients from 19 Gamma Knife facilities in Japan. Major inclusion criteria were 1) newly diagnosed BMs, 2) largest tumor volume of 10.0-33.5 cm3, 3) cumulative intracranial tumor volume ≤ 50 cm3, 4) no leptomeningeal dissemination, 5) no more than 10 tumors, and 6) Karnofsky Performance Status 70{\%} or better. Prescription doses were restricted to between 9.0 and 11.0 Gy in 3-stage GKS and between 11.8 and 14.2 Gy in 2-stage GKS. The total treatment interval had to be within 6 weeks, with at least 12 days between procedures. There were 114 cases in the 3-stage group and 221 in the 2-stage group. Because of the disproportion in patient numbers and the pre-GKS clinical factors between these two GKS groups, a case-matched study was performed using the propensity score matching method. Ultimately, 212 patients (106 from each group) were selected for the case-matched study. Overall survival, tumor progression, neurological death, and radiation-related adverse events were analyzed. Results: In the case-matched cohort, post-GKS median survival time tended to be longer in the 3-stage group (15.9 months) than in the 2-stage group (11.7 months), but the difference was not statistically significant (p = 0.65). The cumu-lative incidences of tumor progression (21.6{\%} vs 16.7{\%} at 1 year, p = 0.31), neurological death (5.1{\%} vs 6.0{\%} at 1 year, p = 0.58), or serious radiation-related adverse events (3.0{\%} vs 4.0{\%} at 1 year, p = 0.49) did not differ significantly. Conclusions: This retrospective multi-institutional study showed no differences between 3-stage and 2-stage GKS in terms of overall survival, tumor progression, neurological death, and radiation-related adverse events. Both 3-stage and 2-stage GKS performed according to the aforementioned protocols are good treatment options in selected patients with large BMs.",
keywords = "Case-matched study, Competing risk analysis, Large brain metastases, Multi-institutional cooperative study, Oncology, Staged Gamma Knife surgery, Stereotactic radiosurgery",
author = "Toru Serizawa and Yoshinori Higuchi and Masaaki Yamamoto and Shigeo Matsunaga and Osamu Nagano and Yasunori Sato and Kyoko Aoyagi and Shoji Yomo and Takao Koiso and Toshinori Hasegawa and Kiyoshi Nakazaki and Akihito Moriki and Takeshi Kondoh and Yasushi Nagatomo and Hisayo Okamoto and Yukihiko Kohda and Hideya Kawai and Satoka Shidoh and Toru Shibazaki and Shinji Onoue and Hiroyuki Kenai and Akira Inoue and Hisae Mori",
year = "2019",
month = "1",
day = "1",
doi = "10.3171/2018.4.JNS172596",
language = "English",
volume = "131",
pages = "227--237",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "1",

}

TY - JOUR

T1 - Comparison of treatment results between 3- And 2-stage Gamma Knife radiosurgery for large brain metastases

T2 - A retrospective multi-institutional study

AU - Serizawa, Toru

AU - Higuchi, Yoshinori

AU - Yamamoto, Masaaki

AU - Matsunaga, Shigeo

AU - Nagano, Osamu

AU - Sato, Yasunori

AU - Aoyagi, Kyoko

AU - Yomo, Shoji

AU - Koiso, Takao

AU - Hasegawa, Toshinori

AU - Nakazaki, Kiyoshi

AU - Moriki, Akihito

AU - Kondoh, Takeshi

AU - Nagatomo, Yasushi

AU - Okamoto, Hisayo

AU - Kohda, Yukihiko

AU - Kawai, Hideya

AU - Shidoh, Satoka

AU - Shibazaki, Toru

AU - Onoue, Shinji

AU - Kenai, Hiroyuki

AU - Inoue, Akira

AU - Mori, Hisae

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: In order to obtain better local tumor control for large (i.e., > 3 cm in diameter or > 10 cm3 in volume) brain metastases (BMs), 3-stage and 2-stage Gamma Knife surgery (GKS) procedures, rather than a palliative dose of stereotactic radiosurgery, have been proposed. Here, authors conducted a retrospective multi-institutional study to compare treatment results between 3-stage and 2-stage GKS for large BMs. Methods: This retrospective multi-institutional study involved 335 patients from 19 Gamma Knife facilities in Japan. Major inclusion criteria were 1) newly diagnosed BMs, 2) largest tumor volume of 10.0-33.5 cm3, 3) cumulative intracranial tumor volume ≤ 50 cm3, 4) no leptomeningeal dissemination, 5) no more than 10 tumors, and 6) Karnofsky Performance Status 70% or better. Prescription doses were restricted to between 9.0 and 11.0 Gy in 3-stage GKS and between 11.8 and 14.2 Gy in 2-stage GKS. The total treatment interval had to be within 6 weeks, with at least 12 days between procedures. There were 114 cases in the 3-stage group and 221 in the 2-stage group. Because of the disproportion in patient numbers and the pre-GKS clinical factors between these two GKS groups, a case-matched study was performed using the propensity score matching method. Ultimately, 212 patients (106 from each group) were selected for the case-matched study. Overall survival, tumor progression, neurological death, and radiation-related adverse events were analyzed. Results: In the case-matched cohort, post-GKS median survival time tended to be longer in the 3-stage group (15.9 months) than in the 2-stage group (11.7 months), but the difference was not statistically significant (p = 0.65). The cumu-lative incidences of tumor progression (21.6% vs 16.7% at 1 year, p = 0.31), neurological death (5.1% vs 6.0% at 1 year, p = 0.58), or serious radiation-related adverse events (3.0% vs 4.0% at 1 year, p = 0.49) did not differ significantly. Conclusions: This retrospective multi-institutional study showed no differences between 3-stage and 2-stage GKS in terms of overall survival, tumor progression, neurological death, and radiation-related adverse events. Both 3-stage and 2-stage GKS performed according to the aforementioned protocols are good treatment options in selected patients with large BMs.

AB - Objective: In order to obtain better local tumor control for large (i.e., > 3 cm in diameter or > 10 cm3 in volume) brain metastases (BMs), 3-stage and 2-stage Gamma Knife surgery (GKS) procedures, rather than a palliative dose of stereotactic radiosurgery, have been proposed. Here, authors conducted a retrospective multi-institutional study to compare treatment results between 3-stage and 2-stage GKS for large BMs. Methods: This retrospective multi-institutional study involved 335 patients from 19 Gamma Knife facilities in Japan. Major inclusion criteria were 1) newly diagnosed BMs, 2) largest tumor volume of 10.0-33.5 cm3, 3) cumulative intracranial tumor volume ≤ 50 cm3, 4) no leptomeningeal dissemination, 5) no more than 10 tumors, and 6) Karnofsky Performance Status 70% or better. Prescription doses were restricted to between 9.0 and 11.0 Gy in 3-stage GKS and between 11.8 and 14.2 Gy in 2-stage GKS. The total treatment interval had to be within 6 weeks, with at least 12 days between procedures. There were 114 cases in the 3-stage group and 221 in the 2-stage group. Because of the disproportion in patient numbers and the pre-GKS clinical factors between these two GKS groups, a case-matched study was performed using the propensity score matching method. Ultimately, 212 patients (106 from each group) were selected for the case-matched study. Overall survival, tumor progression, neurological death, and radiation-related adverse events were analyzed. Results: In the case-matched cohort, post-GKS median survival time tended to be longer in the 3-stage group (15.9 months) than in the 2-stage group (11.7 months), but the difference was not statistically significant (p = 0.65). The cumu-lative incidences of tumor progression (21.6% vs 16.7% at 1 year, p = 0.31), neurological death (5.1% vs 6.0% at 1 year, p = 0.58), or serious radiation-related adverse events (3.0% vs 4.0% at 1 year, p = 0.49) did not differ significantly. Conclusions: This retrospective multi-institutional study showed no differences between 3-stage and 2-stage GKS in terms of overall survival, tumor progression, neurological death, and radiation-related adverse events. Both 3-stage and 2-stage GKS performed according to the aforementioned protocols are good treatment options in selected patients with large BMs.

KW - Case-matched study

KW - Competing risk analysis

KW - Large brain metastases

KW - Multi-institutional cooperative study

KW - Oncology

KW - Staged Gamma Knife surgery

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=85068535012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068535012&partnerID=8YFLogxK

U2 - 10.3171/2018.4.JNS172596

DO - 10.3171/2018.4.JNS172596

M3 - Article

VL - 131

SP - 227

EP - 237

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 1

ER -